Update: ARGEN-X


UP: +11% in last 3 months
Average yearly return: +63%



Argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer.

Fair value: 177.50€

Premium: 16%

Average yearly return: +55%

Buy cheap around: +172.50€

On June the 1rst ARGX announced the closing of its previously announced global offering of an aggregate of 4,207,292 ordinary shares . The gross proceeds from the global offering were approximately $862.5 million (approximately €784.7 million).

Over BillBull

Investment strategist. Never ask me why: 'T.A.' only

Geef een antwoord

Het e-mailadres wordt niet gepubliceerd. Vereiste velden zijn gemarkeerd met *

Deze website gebruikt Akismet om spam te verminderen. Bekijk hoe je reactie-gegevens worden verwerkt.